Partition Bio is a biotechnology company that focuses on developing technologies related to membraneless organelles (MLOs) for cellular physiology and organization. The company aims to apply their understanding of LLPS (Liquid-Liquid Phase Separation) to address dysfunctions associated with MLOs, including neurodegenerative diseases, cancers, and viral infections.

Partition Bio

PartitionBio  
Exploiting a novel proprietary technology platform to develop biomolecular tools for the use in therapeutic and synthetic biology applications.

contact@partitionbio.co.uk

PartitionBio Ltd

𝐏𝐚𝐫𝐭𝐢𝐭𝐢𝐨𝐧𝐁𝐢𝐨 𝐚𝐰𝐚𝐫𝐝𝐞𝐝 𝐠𝐫𝐚𝐧𝐭 𝐭𝐨 𝐞𝐱𝐩𝐥𝐨𝐢𝐭 𝐢𝐭𝐬 𝐧𝐨𝐯𝐞𝐥 𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐬𝐡𝐮𝐭𝐭𝐥𝐞 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 𝐟𝐨𝐫 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐧𝐮𝐜𝐥𝐞𝐢𝐜 𝐚𝐜𝐢𝐝𝐬 𝐝𝐞𝐥𝐢𝐯𝐞𝐫𝐲 
PartitionBio received a grant from the Bill & Melinda Gates Foundation to utilise its proprietary biocondensate-based macromolecule delivery platform for the transfection of cells with nucleic acids. The purpose of the project is to deploy the breakthrough technology as a novel non-viral tool for the introduction of protein-encoding RNA or DNA into human cells. The long-term aim of the work is to enable a more efficient approach for the expression of therapeutic proteins in patients.


𝐀𝐛𝐨𝐮𝐭 𝐏𝐚𝐫𝐭𝐢𝐭𝐢𝐨𝐧𝐁𝐢𝐨
PartitionBio is a Cambridge (UK) based biotech start-up company offering a revolutionary technology platform for the non-viral delivery of a broad spectrum of macromolecules with therapeutic potential across the cell membrane. Possible payloads for the shuttle condensates include antibodies, proteins, peptides and nucleic acids.

Metric
Company Name	Partition Bio
Symbol
MSH ID	UK:CO:PARTITIONBIO
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	UK
Stage
Employee Count	13
Website	partitionbio.co.uk
LinkedIn	partitionbio
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CO

UK:CO:PARTITIONBIO

Partition Bio

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue